Several other brokerages also recently issued reports on MRK. Oddo Bhf set a €125.00 ($154.32) price objective on shares of Merck KGaA and gave the stock a buy rating in a research note on Friday, November 10th. JPMorgan Chase & Co. set a €95.00 ($117.28) price objective on shares of Merck KGaA and gave the stock a neutral rating in a research note on Friday, December 29th. DZ Bank restated a buy rating on shares of Merck KGaA in a research note on Monday, February 12th. UBS Group set a €120.00 ($148.15) price objective on shares of Merck KGaA and gave the stock a buy rating in a research note on Friday, February 16th. Finally, Nord/LB restated a neutral rating on shares of Merck KGaA in a research note on Tuesday, January 2nd. Twelve analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. The stock has a consensus rating of Hold and a consensus price target of €102.86 ($126.99).
Merck KGaA (FRA:MRK) opened at €78.74 ($97.21) on Thursday. Merck KGaA has a twelve month low of €76.60 ($94.57) and a twelve month high of €115.00 ($141.98). The company has a market capitalization of $10,210.00 and a P/E ratio of 13.17.
MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.